Because Neu4 targets to the lysosome, but does not require formation of a multienzyme complex and appears to participate in secretion and reuptake by nearby cells, it might act as an optimal pharmacologic modifier, perhaps through pharmacologic induction, for the treatment of human Tay-Sachs disease. Here, NEU4 is linked to Tay-Sachs disease.